繁體
  • 简体中文
  • 繁體中文
×

熱門資訊> 正文

Clene宣布注册直接发行超过2800万美元

2026-01-09 22:40

  • Clene (CLNN) on Friday announced a registered direct offering priced above market under Nasdaq rules of over $28 million by new and existing investors.
  • On January 9, 2026, Clene entered into securities purchase agreements for the issuance and sale of: 928,333 shares of common stock and accompanying warrants at an offering price of $6.50 per unit for each investor, totaling $6.03 million of gross proceeds, which is expected to fund Clene into the third quarter of 2026;
  • Series A Warrants, which entitle each purchaser to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price.
  • Each Series A Warrant will have an initial exercise price of $6.00 per share. All Series A Warrants will be exercisable immediately upon issuance.  
  • The exercise price of each Series A Warrant will increase to $7.00 per share if either: (a) the warrant is exercised prior to the company’s public announcement of the FDA’s posted PDUFA action date for the CNM-Au8 NDA, which is expected to occur in the first quarter of 2026; or (b) the volume-weighted average price of the Company’s common stock equals or exceeds $10.00 on the measurement date associated with the PDUFA Date Announcement. 
  • The potential gross proceeds from the exercise of the Series A Warrants totals approximately $6.7 million and is expected to fund the company through the end of 2026; and Series B Warrants, which entitle each purchaser to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price.
  • Each Series B Warrant will have an initial exercise price of $6.00 per share. All Series B Warrants will be exercisable immediately upon issuance.  
  • The exercise price of each Series B Warrant is subject to increase based on the timing of exercise and the common stock’s volume-weighted average price in connection with the Company’s public announcement of its receipt of written FDA approval for the CNM-Au8 NDA in ALS.
  • The exercise price will increase to $12.50 per share if the Series B Warrant is exercised before the FDA Approval Announcement. If the Series B Warrant is exercised after the FDA Approval Announcement, it will increase to: (a) $10.00 per share, if the volume-weighted average price of Clene’s common stock on Nasdaq is equal to or greater than $20.00 on the measurement date associated with the FDA Approval Announcement or (b) $12.50 share, if the volume-weighted average price of Clene’s common stock on Nasdaq is equal to or greater than $25.00 on the measurement date. 
  • The potential gross proceeds from the exercise of the Series B Warrants totals about $15.6 million and is expected to fund the company’s commercialization efforts.
  • The Company may redeem or call the Series A Warrants and the Series B Warrants for cancellation if the closing price of the Company’s common stock exceeds the then-effective exercise price on or after the applicable measurement date. 
  • The gross proceeds from the offering are expected to be about $28M.
  • The offering is expected to close on or about January 12, 2026.
  • CLNN -6.7% premarket to $5.57.
  • Source: Press Release

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
（工作日09：30 - 次日05：30）
客戶端：
關注我們：
  • 微信公眾號二維碼

© 2026 深圳市時代華盛網絡科技有限公司版權所有 粵ICP備16068286號